Full Text View
Tabular View
No Study Results Posted
Related Studies
A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Und Fasted Conditions
This study has been completed.
Study NCT00673088   Information provided by Roxane Laboratories
First Received: May 5, 2008   Last Updated: May 21, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Parkinson's Disease
Restless Leg Syndrome
Additional conditions recognized in this trial
Parkinson Disease
Restless Legs Syndrome
Syndrome
More general conditions related to this trial
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Disease
Dyssomnias
Mental Disorders
Movement Disorders
Nervous System Diseases
Neurodegenerative Diseases
Parasomnias
Parkinsonian Disorders
Pathologic Processes
Sleep Disorders
Sleep Disorders, Intrinsic
Interventions listed in this trial
Ropinirole Hydrochloride
Additional drug interventions recognized in this trial
Ropinirole
More general drug interventions related to this trial
Anti-Dyskinesia Agents
Antiparkinson Agents
Central Nervous System Agents
Dopamine Agents
Dopamine Agonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Roxane Laboratories


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services